Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18195952 | 0.80 | ALDH1A1 (0.34) | ALDH1A1KMT2A | |
| SCHEMBL22757765 | 0.78 | CYP2D6 (0.41) | ALDH1A1MEN1LMNAKMT2APOLB | |
| SCHEMBL6222923 | 0.78 | ALDH1A1 (0.38) | ALDH1A1MEN1LMNAKMT2APOLB | |
| SCHEMBL18125153 | 0.78 | CA1 (0.37) | ALDH1A1MEN1LMNAKMT2APOLB | |
| SCHEMBL16272667 | 0.76 | POLB (0.33) | ALDH1A1POLBGRIA4 | |
| SCHEMBL75553 | 0.76 | POLB (0.39) | ALDH1A1MEN1LMNAKMT2APOLB | |
| SCHEMBL10264271 | 0.73 | EPHX1 (0.32) | POLBPER2CRY1CRY2 | |
| SCHEMBL19035633 | 0.73 | PARG (0.32) | ALDH1A1 | |
| SCHEMBL19473392 | 0.73 | CA1 (0.34) | ALDH1A1 | |
| SCHEMBL22063184 | 0.72 | POLB (0.37) | ALDH1A1MEN1LMNAKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584828-B2 | Polyphosphazene polyelectrolytes and uses thereof | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210087342-A1 | POLYPHOSPHAZENE POLYELECTROLYTES AND USES THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2021-03-25 | — | — | US | disclosed |
| US-10858483-B2 | Polyphosphazene polyelectrolytes and uses thereof | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190352468-A1 | POLYPHOSPHAZENE POLYELECTROLYTES AND USES THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2019-11-21 | — | — | US | disclosed |
| EP-2824100-A1 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | Incyte Corporation (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8637557-B2 | Aminothiazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20120220767-A1 | AMINOTHIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220767-A1 | AMINOTHIAZOLE DERIVATIVE | AKT3, AKT2, JAK1 | ALDH1A1 1711/4885MEN1 2152/4885LMNA 4082/4885 |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | ALDH1A1 1275/4885MEN1 4113/4885LMNA 4342/4885 |
| US-10858483-B2 | Polyphosphazene polyelectrolytes and uses thereof | TLR3, TLR9, TLR1 | ALDH1A1 4425/4885MEN1 3526/4885LMNA 4243/4885 |
| US-11584828-B2 | Polyphosphazene polyelectrolytes and uses thereof | TLR3, TLR9, TLR1 | ALDH1A1 4425/4885MEN1 3526/4885LMNA 4243/4885 |
| US-20210087342-A1 | POLYPHOSPHAZENE POLYELECTROLYTES AND USES THEREOF | TLR3, TLR9, TLR1 | ALDH1A1 4425/4885MEN1 3526/4885LMNA 4243/4885 |
| US-20190352468-A1 | POLYPHOSPHAZENE POLYELECTROLYTES AND USES THEREOF | TLR3, TLR9, TLR1 | ALDH1A1 4425/4885MEN1 3526/4885LMNA 4243/4885 |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | IFNG, IRF3, IFNAR1 | ALDH1A1 989/4885MEN1 4492/4885LMNA 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.